ONCT - Oncternal Should Be On Your Radar As Speculative Play Based On Recent Progress
Oncternal Therapeutics (ONCT) may be a good speculative biotech to look into. That's because it has been able to develop a monoclonal antibody, known as cirmtuzumab, which targets the ROR1 protein. The targeting of this ROR1 protein allows cirmtuzumab to be explored in a couple of other combinations. As I will highlight below, this monoclonal antibody is being explored in combination with ibrutinib to treat patients with chronic lymphocytic leukemia ((CLL)) or mantle cell lymphoma ((MCL)). Then, there is the possibility of using the company's drug in combination with a chimeric antigen receptor